Alzprotect is a biotechnology company with a high potential for growth. With an original and innovative scientific strategy, it offers very promising therapeutic solutions for several neurodegenerative diseases – Progressive Supranuclear Palsy and Alzheimer’s disease.
Our mission:
to develop innovative therapeutic solutions to fight neurodegeneration
Alzprotect’s objective is to develop new molecules for the treatment of neurodegenerative diseases. Our team uses innovative treatment strategy and modes of action, quite different from conventional approaches.
The molecules being developed simultaneously tackle the main causes of neurodegeneration. They are intended for the treatment of tauopathies including Alzheimer’s disease (AD) and Progressive Supranuclear Palsy (PSP).
Our ambition:
an innovation partner for the pharmaceutical industry
Alzprotect develops solutions up to the first clinical trials in patients, and partners with pharmaceutical companies for their marketing: collaboration, licensing, etc.
Our asset:
a unique therapeutic offer in the market
AZP2006 has a unique position thanks to a unique mechanism of action that simultaneously addresses the main causes of the disease: beta-amyloid peptide, Tau protein, oxidative stress and neuroinflammation. This multiple action may both stop the disease and restore cognitive abilities.
The therapeutic potential of AZP2006 is therefore much higher than our competitors’ molecules.
Our objectives:
With a very promising ongoing phase 2a study and the orphan designation granted in Europe and in the United States, Alzprotect continues to raise funds to support the expansion of its therapeutic strategy to Alzheimer’s disease and Parkinson’s disease – two major public health challenges worldwide.